L Pedersen1, L L Christensen2, S M Pedersen3, M Andersen2. 1. Department of Clinical Chemistry, Holbæk Hospital, Smedelundsgade 60, 4300, Holbæk, Denmark. liseped@regionsjaelland.dk. 2. Department of Endocrinology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark. 3. Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark.
Abstract
OBJECTIVES: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate. DESIGN: Randomized, double-blinded, placebo-controlled study. SETTING: Odense Androgen Study-the effect of Testim and training in hypogonadal men. PARTICIPANTS: Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement. INTERVENTION: Participants were randomized to receive 5-10 ggel/50-100 mg testosterone (Testim®, Ipsen, France) or 5-10 g gel/placebo. RESULTS: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone. CONCLUSION: Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.
RCT Entities:
OBJECTIVES: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate. DESIGN: Randomized, double-blinded, placebo-controlled study. SETTING: Odense Androgen Study-the effect of Testim and training in hypogonadal men. PARTICIPANTS: Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement. INTERVENTION: Participants were randomized to receive 5-10 g gel/50-100 mg testosterone (Testim®, Ipsen, France) or 5-10 g gel/placebo. RESULTS: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone. CONCLUSION: Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.
Authors: Jerry Meng; Claes Ohlsson; Gail A Laughlin; Michel Chonchol; Christina L Wassel; Osten Ljunggren; Magnus K Karlsson; Dan Mellstrom; Eric S Orwoll; Elizabeth Barrett-Connor; Joachim H Ix Journal: Kidney Int Date: 2010-06-09 Impact factor: 10.612
Authors: L Frederiksen; K Højlund; D M Hougaard; T H Mosbech; R Larsen; A Flyvbjerg; J Frystyk; K Brixen; M Andersen Journal: Eur J Endocrinol Date: 2011-12-21 Impact factor: 6.664
Authors: Chris J Malkin; Peter J Pugh; Richard D Jones; Dheeraj Kapoor; Kevin S Channer; T Hugh Jones Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: David A Morrow; Yunmei Wang; Kevin Croce; Masashi Sakuma; Marc S Sabatine; Huiyun Gao; Aruna D Pradhan; Aileen M Healy; Jacki Buros; Carolyn H McCabe; Peter Libby; Christopher P Cannon; Eugene Braunwald; Daniel I Simon Journal: Am Heart J Date: 2007-11-01 Impact factor: 4.749
Authors: Dongxing Zhu; Patrick W F Hadoke; Junxi Wu; Alex T Vesey; Daniel A Lerman; Marc R Dweck; David E Newby; Lee B Smith; Vicky E MacRae Journal: Sci Rep Date: 2016-04-20 Impact factor: 4.379
Authors: Thomas Ebert; Sven-Christian Pawelzik; Anna Witasp; Samsul Arefin; Sam Hobson; Karolina Kublickiene; Paul G Shiels; Magnus Bäck; Peter Stenvinkel Journal: Toxins (Basel) Date: 2020-04-04 Impact factor: 4.546